All

TxCell announces start of phase IIb clinical trial with Ovasave® for refractory Crohn’s disease
4 December 2014

TxCell announces start of phase IIb clinical trial with Ovasave® for refractory Crohn’s disease

TxCell SA (FR0010127662 – TXCL), a biotechnology company developing novel and innovative, cost-effective personalized T cell immunotherapies using antigen specific regulatory...

Read the press release

By continuing your browsing on this site, you accept the use of cookies to carry out statistics of anonymous visits. Read more

Authorize Refuse